Olaparib

Generic Name: Olaparib

Brand Names: Lynparza

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₃FN_₄O_₃

CAS Number: 763113-22-0

Unique Ingredient Identifier: WOH1JD9AR8

Background: Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2. PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death.
...

Indication: Ovarian cancer

Olaparib is indicated for the maintenance treatment of adults with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.
...

Associated Conditions: Advanced Epithelial Ovarian Cancer, Advanced Fallopian Tube Carcinoma, Advanced Primary Peritoneal Carcinoma, High risk, early breast cancer, Hormone Receptor Positive Breast Carcinoma, Locally Advanced Breast Cancer (LABC), Metastatic Adenocarcinoma of the Pancreas, Metastatic Breast Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Pancreatic Adenocarcinoma Metastatic, Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Stage I Breast Cancer, Advanced high-grade epithelial ovarian cancer, Advanced, high-grade Primary Peritoneal Cancer, High-grade advanced Fallopian Tubes Cancer, Recurrent platinum sensitive primary peritoneal cancer, Relapsed Platinum-Sensitive Epithelial Ovarian Cancer, Relapsed platinum sensitive primary peritoneal cancer, Relapsed platinum-sensitive fallopian tube cancer

Associated Therapies: Maintenance therapy

Clinical Trials

Parp Inhibitor in Advanced Non-Small Cell Lung Cancer (PIN)

Phase 2

Conditions: Non-small Cell Lung Cancer

Interventions: Other: Placebo
Drug: Olaparib

First Posted Date: 2013-02-11

Last Posted Date: 2018-10-26

Lead Sponsor: Lisette Nixon

Target Recruit Count: 70

Registration Number: NCT01788332

Locations: 🇬🇧
Blackpool Victoria Hospital, Blackpool, United Kingdom
🇬🇧
Queen's Hospital, Burton Upon Trent, United Kingdom
🇬🇧
Derby Teaching Hospitals NHS Foundation Trust, Derby, United Kingdom

and more 17 locations

Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History

Phase 1

Completed

Conditions: Squamous Cell Carcinoma of the Head and Neck

Interventions: Drug: Olaparib
Drug: Cetuximab
Radiation: Radiation Therapy

First Posted Date: 2013-01-01

Last Posted Date: 2019-09-23

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 17

Registration Number: NCT01758731

Locations: 🇺🇸
University of Colorado Denver, Denver, Colorado, United States

TOPARP: A Phase II Trial of Olaparib in Patients With Advanced Castration Resistant Prostate Cancer

Phase 2

Conditions: Adenocarcinoma of the Prostate

Interventions: Drug: Olaparib

First Posted Date: 2012-09-11

Last Posted Date: 2019-08-15

Lead Sponsor: Institute of Cancer Research, United Kingdom

Target Recruit Count: 148

Registration Number: NCT01682772

Locations: 🇬🇧
University College Hospital London, London, United Kingdom
🇬🇧
Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom

Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer

Phase 2

Withdrawn

Conditions: Ovarian Cancer
Peritoneal Cancer
Fallopian Tube Cancer

Interventions: Drug: Olaparib

First Posted Date: 2012-08-10

Last Posted Date: 2012-08-21

Lead Sponsor: Dana-Farber Cancer Institute

Registration Number: NCT01661868

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer

Phase 1

Conditions: Stage IV Ovarian Cancer
Uterine Cancer
Stage III Ovarian Cancer

Interventions: Drug: Olaparib
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2012-07-26

Last Posted Date: 2018-03-23

Lead Sponsor: Swedish Medical Center

Target Recruit Count: 52

Registration Number: NCT01650376

Locations: 🇺🇸
Pacific Gynecology Specialists, Seattle, Washington, United States
🇺🇸
Swedish Cancer Institute Ballard Campus, Seattle, Washington, United States
🇺🇸
Swedish Cancer Institute Edmonds Campus, Edmonds, Washington, United States

and more 2 locations

Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma

Phase 2

Completed

Conditions: Ewing's Sarcoma

Interventions: Drug: Olaparib

First Posted Date: 2012-04-24

Last Posted Date: 2017-05-19

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 12

Registration Number: NCT01583543

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Olaparib Dose Escalating Trial + Concurrent RT With or Without Cisplatin in Locally Advanced NSCLC

Phase 1

Completed

Conditions: NSCLC

Interventions: Drug: Olaparib
Drug: Cisplatin
Radiation: Radiation

First Posted Date: 2012-03-23

Last Posted Date: 2020-03-17

Lead Sponsor: The Netherlands Cancer Institute

Target Recruit Count: 28

Registration Number: NCT01562210

Locations: 🇳🇱
Netherlands Cancer Institute - Antoni van Leeuwenhoek Ziekenhuis (NKI-AVL), Amsterdam, Noord-Holland, Netherlands

Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone

Phase 1

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Gefitinib
Drug: Olaparib

First Posted Date: 2012-01-20

Last Posted Date: 2024-06-28

Lead Sponsor: Spanish Lung Cancer Group

Target Recruit Count: 186

Registration Number: NCT01513174

Locations: 🇪🇸
ICO Hospitalet, Hospitalet de Llobregat, Barcelona, Spain
🇪🇸
H. Teresa Herrera, La Coruña, Spain
🇪🇸
H. Germans Trias i Pujol, Badalona, Barcelona, Spain

and more 2 locations